Christopher Codispoti is a Rheumatology/Immunology physician. OpenAlex indexes 63 publications with 896 citations (h-index 18).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6410 Fannin St Ste 720
Houston, TX 770305205
Telephone
713-486-0340Provider last certified this registry record 4 Sept 2024.
Industry payments
17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Blueprint Medicines CorporationProgram year20254 payments
- AstraZeneca Pharmaceuticals LPProgram year20258 payments
- Novartis Pharmaceuticals CorporationProgram year20258 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
95.1%Corticosteroid27.2%Fluticasone Propionate74%Dulera11%Mometasone Furoate8%Breyna8%Part D<11 patientsHistamine-1 Receptor Antagonist24.4%Azelastine Hcl88%Levocetirizine Dihydrochloride12%Part D<11 patients+ 4 more classes in this area
Dermatology
4.9%Interleukin-4 Receptor alpha Antagonist4.9%Dupixent Pen50%Dupixent Syringe50%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Impact of climate change on aerobiology, rhinitis, and allergen immunotherapy: Work Group Report from the Aerobiology, Rhinitis, Rhinosinusitis & Ocular Allergy, and Immunotherapy, Allergen Standardization & Allergy Diagnostics Committees of the American Academy of Allergy, Asthma & Immunology
Journal of Allergy and Clinical Immunology
2025 - Cost-effectiveness of tiotropium and salmeterol add-on to low-dose beclomethasone compared to medium-dose beclomethasone in patients with uncontrolled moderate asthma
Journal of Allergy and Clinical Immunology
2025 - Patient-Centered Practice Guidelines: GRADEing Evidence to Incorporate Certainty, Balance Between Benefits and Harms, Equity, Feasibility, and Cost-Effectiveness
The Journal of Allergy and Clinical Immunology In Practice
2024 - Pharmacoequity and Biologics in the Allergy Clinic: Providing the Right Care, at the Right Time, Every Time, to Everyone
The Journal of Allergy and Clinical Immunology In Practice
2024 - Food sensitization and cardiovascular mortality: An intriguing association in need of further study
Journal of Allergy and Clinical Immunology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”